PF-Atlas › Clinical Trials › NCT00112359

International Safety and Efficacy Study of Aztreonam for Inhalation Solution in Cystic Fibrosis Patients With P. Aeruginosa

AZLI 75 mg three times a day · ANZCTR · Phase 3

Registry ID
NCT00112359
Phase
Phase 3
Status
Completed
Drug / intervention
AZLI 75 mg three times a day (TID)
Mechanism
ANZCTR
Sponsor
Gilead Sciences
Start
2005-05
Enrollment
166
Locations
53

About this trial

The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).

View NCT00112359 on ClinicalTrials.gov →

Explore related

All AZLI 75 mg three times a day trialsANZCTR mechanismAll IPF trials

Related trials

Ifenprodil — NCT04318704Inhaled mannitol — NCT00669331PTI-808 — NCT03251092BI 1819479 — NCT06335303AP01 — NCT06951217CMS — NCT03093974
Medical disclaimer. This page summarizes public trial data for NCT00112359 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.